Stock Worth Watching: 0.98 is CVS Caremark Corp’s (NYSE:CVS) Institutional Investor Sentiment

November 24, 2016 - By Linda Rogers   ·   0 Comments

Stock Worth Watching: 0.98 is CVS Caremark Corp's (NYSE:CVS) Institutional Investor Sentiment

Sentiment for CVS Caremark Corp (NYSE:CVS)

CVS Caremark Corp (NYSE:CVS) institutional sentiment decreased to 0.98 in 2016 Q2. Its down -0.02, from 1 in 2016Q1. The ratio has dropped, as 641 investment managers increased or opened new holdings, while 641 sold and reduced their positions in CVS Caremark Corp. The investment managers in our partner’s database now hold: 833.68 million shares, down from 895.55 million shares in 2016Q1. Also, the number of investment managers holding CVS Caremark Corp in their top 10 holdings decreased from 208 to 149 for a decrease of 59. Sold All: 67 Reduced: 574 Increased: 544 New Position: 97.

CVS Health Corporation, together with its subsidiaries , is a pharmacy company. The company has a market cap of $77.92 billion. The Firm operates through three business divisions: Pharmacy Services, Retail/LTC and Corporate. It has a 15.72 P/E ratio. The Firm offers a range of services and products, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.

The stock increased 0.11% or $0.08 on November 23, hitting $73.67. About 6.60M shares traded hands. CVS Health Corp (NYSE:CVS) has declined 27.38% since April 22, 2016 and is downtrending. It has underperformed by 32.79% the S&P500.

Analysts await CVS Health Corp (NYSE:CVS) to report earnings on February, 14. They expect $1.67 EPS, up 9.15% or $0.14 from last year’s $1.53 per share. CVS’s profit will be $1.77 billion for 11.03 P/E if the $1.67 EPS becomes a reality. After $1.64 actual EPS reported by CVS Health Corp for the previous quarter, Wall Street now forecasts 1.83% EPS growth.

According to Zacks Investment Research, “CVS Health Corporation is a pharmacy innovation company. Its offerings include pharmacy benefit management services, mail order, retail and specialty pharmacy, disease management programs, and retail clinics. The Company serves employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS/pharmacy, RxAmerica, Accordant, SilverScript, and Novologix names. CVS Health Corporation, formerly known as CVS Caremark Corporation, is headquartered in Woonsocket, Rhode Island.”

Cortland Associates Inc Mo holds 11.14% of its portfolio in CVS Health Corp for 530,412 shares. Dsc Advisors L.P. owns 152,004 shares or 9.16% of their US portfolio. Moreover, Veritas Investment Management Llp has 9.09% invested in the company for 492,176 shares. The New York-based Grisanti Capital Management Llc has invested 8.03% in the stock. Kdi Capital Partners Llc, a North Carolina-based fund reported 260,992 shares.#img1#

CVS Health Corp (NYSE:CVS) Ratings Coverage

Ratings analysis reveals 73% of CVS Health’s analysts are positive. Out of 15 Wall Street analysts rating CVS Health, 11 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $90 while the high is $132. The stock’s average target of $115.07 is 56.20% above today’s ($73.67) share price. CVS was included in 23 notes of analysts from July 22, 2015. Oppenheimer maintained the shares of CVS in a report on Monday, November 2 with “Outperform” rating. The rating was initiated by UBS with “Buy” on Thursday, October 6. Deutsche Bank maintained CVS Health Corp (NYSE:CVS) on Thursday, August 20 with “Hold” rating. Morgan Stanley downgraded CVS Health Corp (NYSE:CVS) rating on Monday, June 20. Morgan Stanley has “Equal-Weight” rating and $104 price target. The rating was maintained by S&P Research with “Strong Buy” on Monday, November 2. The firm has “Outperform” rating by Robert W. Baird given on Friday, January 22. The rating was maintained by Oppenheimer on Thursday, December 17 with “Outperform”. The company was maintained on Monday, May 9 by Citigroup. Barclays Capital initiated it with “Overweight” rating and $110 target price in Friday, December 18 report. The stock of CVS Health Corp (NYSE:CVS) has “Overweight” rating given on Monday, November 2 by JP Morgan.

CVS Company Profile

CVS Health Corporation, incorporated on August 22, 1996, together with its subsidiaries (CVS Health), is a pharmacy company. The Firm operates through three business divisions: Pharmacy Services, Retail/LTC and Corporate. The Firm offers a range of services and products, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare. The Pharmacy Services Segment provides a range of pharmacy benefit management (PBM) solutions. The Retail Pharmacy segment includes retail drugstores, online retail pharmacy Websites and its retail healthcare clinics.

More news for CVS Health Corp (NYSE:CVS) were recently published by: Fool.com, which released: “Why CVS Health Corp Stock Is Falling Today” on November 08, 2016. Prnewswire.com‘s article titled: “CVS Health Corporation To Hold Third Quarter 2016 Conference Call” and published on October 28, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Linda Rogers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>